Please assess the completion status of the following clinical trial:

Trial Title: Obesity and Nonalcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~All~* 18 - 45 years old~* Class I obesity, i.e. Body Mass Index (BMI) between 30 and 45.~* weight less than 300 lbs.~Exclusion Criteria:~* Active or previous infection with hepatitis B or C, as well as other liver disease.~* History of alcohol abuse~* Diabetes~* Medications that cause liver damage or steatosis.~* Women who are pregnant or lactating.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- NAFLD-Niacin (Type: EXPERIMENTAL): Subjects, having previously diagnosed with NAFLD, were given Niacin for 16 weeks. The dosage was 500mg/day for week 1, 1000mg/day for week 2, 1500mg/day for week three and 2000mg/day for weeks 4 through 16.
- Control (Type: NO_INTERVENTION): Subjects were found to have intrahepatic triglyceride levels below the threshold for Non-Alcoholic Fatty Liver Disease (NAFLD). For this study that threshold was set at 10% intrahepatic triglyceride content as determined by magnetic resonance spectroscopy. These control subjects did not participate in any intervention. Only baseline features were characterized for this arm.
- NAFLD-fenofibrate (Type: EXPERIMENTAL): Subjects diagnosed with NAFLD were randomized to fenofibrate, an oral medication, nightly for eight weeks. Subjects will be given a dose of 200mg/day.
- NAFLD-placebo (Type: PLACEBO_COMPARATOR): These subjects were diagnosed with Non-Alcoholic Fatty Liver Disease (NAFLD) and received an 8 week course of a placebo pill. Their baseline characteristics were averaged into the overall NAFLD baseline characteristics along with the baseline data for the two intervention groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).